Although combination approaches of venetoclax with Bruton Tyrosine Kinase (BTK) inhibitors and/or anti-CD20 monoclonal antibodies in CLL or venetoclax with hypomethylating agents in AML have improved outcomes, none of these regimens have proven to be curative, suggesting the persistence of treatment resistant tumor cells [33–36]. Here, BTK is linked to neoplasm.